Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor saha to overcome bcr-abl-mediated drug resistance

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Carew, J. S.
  • Nawrocki, S. T.
  • Kahue, C. N.
  • Zhang, H.
  • Yang, C. Y.
  • Chung, L.
  • Houghton, J. A.
  • Huang, P.
  • Giles, F. J.
  • Cleveland, John

publication date

  • July 2007

journal

  • Blood  Journal

abstract

  • Novel therapeutic strategies are needed to address the emerging problem of imatinib resistance. The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) is being evaluated for imatinib-resistant chronic myelogenous leukemia (CML) and has multiple cellular effects, including the induction of autophagy and apoptosis. Considering that autophagy may promote cancer cell survival, we hypothesized that disrupting autophagy would augment the anticancer activity of SAHA. Here we report that drugs that disrupt the autophagy pathway dramatically augment the antineoplastic effects of SAHA in CML cell lines and primary CML cells expressing wild-type and imatinib-resistant mutant forms of Bcr-Abl, including T315I. This regimen has selectivity for malignant cells and its efficacy was not diminished by impairing p53 function, another contributing factor in imatinib resistance. Disrupting autophagy by chloroquine treatment enhances SAHA-induced superoxide generation, triggers relocalization and marked increases in the lysosomal protease cathepsin D, and reduces the expression of the cathepsin-D substrate thioredoxin. Finally, knockdown of cathepsin D diminishes the potency of this combination, demonstrating its role as a mediator of this therapeutic response. Our data suggest that, when combined with HDAC inhibitors, agents that disrupt autophagy are a promising new strategy to treat imatinib-refractory patients who fail conventional therapy.

subject areas

  • Antineoplastic Agents
  • Autophagy
  • Cathepsin D
  • Cell Line, Tumor
  • Chloroquine
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Enzyme Inhibitors
  • Fusion Proteins, bcr-abl
  • Histone Deacetylase Inhibitors
  • Humans
  • Hydroxamic Acids
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
scroll to property group menus

Identity

PubMed Central ID

  • PMC1896119

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood-2006-10-050260

PubMed ID

  • 17363733
scroll to property group menus

Additional Document Info

start page

  • 313

end page

  • 322

volume

  • 110

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support